ContraFect Corporation (CFRXQ)
Company Description
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States.
Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus.
The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections.
It also developing CF-296, an osteomyelitis and PJI which is in preclinical trailers for the treatment of joint infections.
In addition, the company developing Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients.
Further, It develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis.
The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens.
ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York. On December 4, 2023, ContraFect Corporation filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.
Country | United States |
Founded | 2008 |
IPO Date | Jul 29, 2014 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 23 |
CEO | Roger Pomerantz |
Contact Details
Address: 28 Wells Avenue, 3rd Floor Yonkers, New York 10701 United States | |
Phone | 914-207-2300 |
Stock Details
Ticker Symbol | CFRXQ |
Exchange | OTCMKTS |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001478069 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Michael Messinger CPA | Chief Executive Officer, President, Chief Financial Officer and Principal Accounting Officer |
Natalie Bogdanos J.D. | General Counsel, Corporate Secretary and Data Protection Officer |
Matthew Salamone P.H.R., SPHR | Vice President of Human Resources |
Dr. Gary Woodnutt | Senior Vice President of Translational Sciences and Preclinical Development |
Dr. William Garrett Nichols M.D., M.S. | Interim Chief Medical Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Dec 27, 2023 | 25-NSE | Filing |
Dec 5, 2023 | 8-K | Current Report |
Nov 15, 2023 | 8-K | Current Report |
Nov 14, 2023 | 10-Q | Quarterly Report |
Nov 8, 2023 | 8-K | Current Report |
Nov 3, 2023 | 424B3 | Prospectus |
Nov 2, 2023 | EFFECT | Notice of Effectiveness |
Oct 30, 2023 | S-1 | General form for registration of securities under the Securities Act of 1933 |
Oct 24, 2023 | S-1 | General form for registration of securities under the Securities Act of 1933 |